✦ LIBER ✦

Cost and risk benefit in the management of clinical stage II nonseminomatous testicular tumors

✍ Scribed by Jack Baniel; Bruce J. Roth; Richard S. Foster; John P. Donohue

Publisher: John Wiley and Sons
Year: 1995
Tongue: English
Weight: 711 KB
Volume: 75
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19950615)75:12<2897::aid-cncr2820751217>3.0.co;2-r

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

MIB-1 immunohistochemistry in clinical S

MIB-1 immunohistochemistry in clinical Stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis

✍ Peter Albers; Erhard Bierhoff; Daniela Neu; Rolf Fimmers; Nicolas Wernert; Stefa 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 2 views

all patients underwent retroperitoneal lymph node dissection) were retrospectively cal Center,

DNA ploidy in the primary tumor from pat

DNA ploidy in the primary tumor from patients with nonseminomatous testicular germ cell tumors clinical stage I

✍ Sophie D. Fosså; Jahn Marthin Nesland; Håkon Wæhre; Øystein Åmellem; Erik O. Pet 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 396 KB 👁 2 views

Early resection of residual tumor during

Early resection of residual tumor during cisplatin, vinblastine, bleomycin combination chemotherapy in stage III and bulky stage II nonseminomatous testicular cancer

✍ Giorgio Pizzocaro; Roberto Salvioni; Massimo Pasi; Fulvio Zanoni; Angelo Milani; 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 630 KB

Sixty consecutive patients with Stage I11 or bulky Stage II nonseminatous germinal testis tumors were treated with cisplatin, vinblastine, bleomycin combination chemotherapy (PVB). One patient died of acute toxicity after the first course of therapy, 16 entered complete remission (CR) after two or t

Immunohistochemical assessment of tumor

Immunohistochemical assessment of tumor proliferation and volume of embryonal carcinoma identify patients with clinical stage a nonseminomatous testicular germ cell tumor at low risk for occult metastasis

✍ Peter Albers; Greg A. Miller; Attilio Orazi; Thomas M. Ulbright; Jutta Albers; J 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 642 KB

Favorable outcome in clinically stage II

Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression

✍ Inge S. van Houdt; Berbel J.R. Sluijter; Laura M. Moesbergen; Wim M. Vos; Tanja 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 296 KB 👁 1 views

## Abstract In this study we investigated whether the presence of specific populations of tumor infiltrating lymphocytes (TILs) in diagnostic primary melanoma biopsies are related to outcome in clinically stage II melanoma patients. Moreover, we investigated whether the presence of TILs correlates